Vol. 12, Issue 1 (2023)

Author(s):
Vasudhar Bhat SV, Uma Radhakrishnan, Shynu M, Naicy Thomas, Varuna P Panicker, Ambily R and Akshatha G Desai

Abstract:
Cancer is one of the leading causes of death all over the world. A multifaceted approach is very much essential to treat the cancer patients along with the surgical interventions. One such approach is by using chemotherapeutic drugs. Cisplatin is one of the most commonly used chemotherapeutic drugs in use. Its exhibits its effects by binding to DNA and causing single stranded breaks. The present study was aimed to evaluate the anticancer property of Cisplatin in Daltons Lymphoma Ascites Cancer cell lines. Half-maximal inhibitory concentration (IC₅₀) of the drug was calculated as 10.76 μg/mL by performing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) Assay which revealed a significant concentration-dependent cytotoxicity. The mode of action of the drug was studied in detail by subjecting the Cisplatin treated cells to Acridine Orange / Ethidium Bromide (AO/EB) staining and assessing the relative expression of Caspase-3 and VEGF genes. In AO/EB staining the cells treated with different concentrations of cisplatin emitted red florescence indicating apoptosis. The real time quantification revealed about 190-fold upregulation of Caspase-3 and 14-fold downregulation of VEGF in cells treated with IC₅₀ concentration of Cisplatin in comparison with control. These findings of the present study show that alternative effects like antiangiogenic effect along with activation of apoptotic pathway to be responsible of antineoplastic activity of Cisplatin.